Press Releases

Press Releases

Filters
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
Viatris’ Dividend Reinvestment and Share Purchase Plan
Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022
Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
Viatris to Participate in Upcoming Investor Conferences
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Add
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
Displaying 1 - 10 of 45